The viability data suggest that compound 5 for the SH-SY5Y cell line and compounds 9 and 13 for the MCF7 cell line exhibit higher potential utility.These novel compounds hold promise as potential PARP-1 inhibitorsfor the development of targeted therapeutics against cancer. This evidence concerns the gene PARP1 and cancer.